{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:16:49Z","timestamp":1793143009600,"version":"4.5.0"},"reference-count":171,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000090","name":"United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-22-1-016"],"award-info":[{"award-number":["W81XWH-22-1-016"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["2020101"],"award-info":[{"award-number":["2020101"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","award":["71-22"],"award-info":[{"award-number":["71-22"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA279044"],"award-info":[{"award-number":["R01CA279044"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA286652"],"award-info":[{"award-number":["R01CA286652"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Renal cell carcinomas (RCC) comprise multiple molecularly distinct cancers but most are treated empirically with therapies designed for clear cell RCC (ccRCC), the most common subtype, due to incomplete understanding of subtype-specific biology. We analyzed single-cell transcriptomes and chromatin accessibility profiles from translocation renal cell carcinoma (tRCC), an aggressive RCC defined by oncogenic\n                    <jats:italic>TFE3<\/jats:italic>\n                    gene fusions. We show that, despite arising from a proximal tubule cell of origin similar to ccRCC, tRCCs display distinct oncogenic programs and an immunosuppressive tumor microenvironment (TME). tRCCs exhibit six conserved tumor meta-programs, including epithelial-mesenchymal transition (EMT) and proximal tubule identity programs whose balance is regulated by TFE3 fusion activity. The fusion-driven EMT program drives a suppressive TME marked by progenitor-exhausted CD8\u2009+\u2009T cells, anti-inflammatory SPP1+ macrophages, and matrix-associated fibroblasts. Our findings highlight unique TFE3 fusion-driven biology in tRCC, explaining its reduced immunotherapy responsiveness relative to ccRCC, and suggesting strategies for targeting fusion-driven oncogenic programs and TME reprogramming.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-76858-w","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:05:26Z","timestamp":1787720726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6861-4442","authenticated-orcid":false,"given":"Prathyusha","family":"Konda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6049-5090","authenticated-orcid":false,"given":"Alexandra J.","family":"Wakolbinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yantong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Roberti de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0848-9843","authenticated-orcid":false,"given":"Yasmin L.","family":"Nabil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary N.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1111-6854","authenticated-orcid":false,"given":"Maxwell D.","family":"Seager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riva","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8027-5877","authenticated-orcid":false,"given":"Jiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed","family":"Matar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5081-8850","authenticated-orcid":false,"given":"Jinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Y.","family":"Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseman B.","family":"Sheshdeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Einstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashika","family":"Rustagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwesha","family":"Nag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Thorner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8825-7158","authenticated-orcid":false,"given":"Cheng-Zhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-4444","authenticated-orcid":false,"given":"Eliezer M.","family":"Van Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5000-9105","authenticated-orcid":false,"given":"Sabina","family":"Signoretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1856-3023","authenticated-orcid":false,"given":"Srinivas R.","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"76858_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","volume":"70","author":"H Moch","year":"2016","unstructured":"Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E. & Ulbright, T. M. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur. Urol. 70, 93\u2013105 (2016).","journal-title":"Eur. Urol."},{"key":"76858_CR2","doi-asserted-by":"publisher","first-page":"e438642","DOI":"10.1200\/EDBK_438642","volume":"44","author":"NJ Salgia","year":"2024","unstructured":"Salgia, N. J., Zengin, Z. B., Pal, S. K. & Dizman, N. Renal cell carcinoma of variant histology: new biologic understanding leads to therapeutic advances. Am. Soc. Clin. Oncol. Educ. Book 44, e438642 (2024).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"76858_CR3","doi-asserted-by":"publisher","first-page":"e162480","DOI":"10.1172\/JCI162480","volume":"132","author":"WG Kaelin","year":"2022","unstructured":"Kaelin, W. G. Von Hippel\u2013Lindau disease: insights into oxygen sensing, protein degradation, and cancer. J. Clin. Invest. 132, e162480 (2022).","journal-title":"J. Clin. Invest."},{"key":"76858_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S1535-6108(02)00043-0","volume":"1","author":"K Kondo","year":"2002","unstructured":"Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, W. G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237\u2013246 (2002).","journal-title":"Cancer Cell"},{"key":"76858_CR5","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1128\/MCB.25.13.5675-5686.2005","volume":"25","author":"RR Raval","year":"2005","unstructured":"Raval, R. R. et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell Biol. 25, 5675\u20135686 (2005).","journal-title":"Mol. Cell Biol."},{"key":"76858_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrc3844","volume":"15","author":"L Gossage","year":"2015","unstructured":"Gossage, L., Eisen, T. & Maher, E. R. VHL, the story of a tumour suppressor gene. Nat. Rev. Cancer 15, 55\u201364 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"76858_CR7","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.hoc.2023.05.023","volume":"37","author":"E Saad","year":"2023","unstructured":"Saad, E. et al. Novel immune therapies for renal cell carcinoma: looking beyond the programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4 axes. Hematol. Oncol. Clin. North Am. 37, 1027\u20131040 (2023).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"76858_CR8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.hoc.2023.05.022","volume":"37","author":"RM Saliby","year":"2023","unstructured":"Saliby, R. M. et al. Novel targeted therapies for renal cell carcinoma: building on the successes of vascular endothelial growth factor and mTOR inhibition. Hematol. Oncol. Clin. North Am. 37, 1015\u20131026 (2023).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"76858_CR9","doi-asserted-by":"publisher","first-page":"e2425251","DOI":"10.1001\/jamanetworkopen.2024.25251","volume":"7","author":"JT Brown","year":"2024","unstructured":"Brown, J. T. Adjuvant therapy for non\u2013clear cell renal cell carcinoma\u2014the ascent continues. JAMA Netw. Open 7, e2425251 (2024).","journal-title":"JAMA Netw. Open"},{"key":"76858_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMra1601333","volume":"376","author":"TK Choueiri","year":"2017","unstructured":"Choueiri, T. K. & Motzer, R. J. Systemic therapy for metastatic renal-cell carcinoma. N. Engl. J. Med. 376, 354\u2013366 (2017).","journal-title":"N. Engl. J. Med."},{"key":"76858_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrurol.2014.162","volume":"11","author":"EC Kauffman","year":"2014","unstructured":"Kauffman, E. C. et al. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat. Rev. Urol. 11, 465\u2013475 (2014).","journal-title":"Nat. Rev. Urol."},{"key":"76858_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110190","volume":"38","author":"Z Bakouny","year":"2022","unstructured":"Bakouny, Z. et al. Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Rep. 38, 110190 (2022).","journal-title":"Cell Rep."},{"key":"76858_CR13","doi-asserted-by":"publisher","first-page":"E1110","DOI":"10.3390\/cancers11081110","volume":"11","author":"A Cali\u00f2","year":"2019","unstructured":"Cali\u00f2, A., Segala, D., Munari, E., Brunelli, M. & Martignoni, G. MiT family translocation renal cell carcinoma: from the early descriptions to the current knowledge. Cancers 11, E1110 (2019).","journal-title":"Cancers"},{"key":"76858_CR14","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/cncr.31578","volume":"124","author":"MM Cajaiba","year":"2018","unstructured":"Cajaiba, M. M. et al. The classification of pediatric and young adult renal cell carcinomas registered on the Children\u2019s Oncology Group (COG) protocol AREN03B2 after focused genetic testing. Cancer 124, 3381\u20133389 (2018).","journal-title":"Cancer"},{"key":"76858_CR15","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1158\/1078-0432.CCR-08-1183","volume":"15","author":"Y Komai","year":"2009","unstructured":"Komai, Y. et al. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin. Cancer Res. 15, 1170\u20131176 (2009).","journal-title":"Clin. Cancer Res."},{"key":"76858_CR16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/PAS.0b013e31824f24a6","volume":"36","author":"M Zhong","year":"2012","unstructured":"Zhong, M. et al. Translocation renal cell carcinomas in adults: a single-institution experience. Am. J. Surg. Pathol. 36, 654\u2013662 (2012).","journal-title":"Am. J. Surg. Pathol."},{"key":"76858_CR17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/oncolo\/oyac262","volume":"28","author":"O Alhalabi","year":"2023","unstructured":"Alhalabi, O. et al. Immune checkpoint therapy combinations in adult advanced MiT family translocation renal cell carcinomas. Oncologist 28, 433\u2013439 (2023).","journal-title":"Oncologist"},{"key":"76858_CR18","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.1002\/cncr.25512","volume":"116","author":"TK Choueiri","year":"2010","unstructured":"Choueiri, T. K. et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 116, 5219\u20135225 (2010).","journal-title":"Cancer"},{"key":"76858_CR19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(18)30907-0","volume":"20","author":"NM Chanz\u00e1","year":"2019","unstructured":"Chanz\u00e1, N. M. et al. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 20, 581\u2013590 (2019).","journal-title":"Lancet Oncol."},{"key":"76858_CR20","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/oncolo\/oyac158","volume":"27","author":"J Thouvenin","year":"2022","unstructured":"Thouvenin, J. et al. Efficacy of cabozantinib in metastatic MiT family translocation renal cell carcinomas. Oncologist 27, 1041\u20131047 (2022).","journal-title":"Oncologist"},{"key":"76858_CR21","doi-asserted-by":"publisher","first-page":"5735","DOI":"10.1016\/j.cell.2024.07.038","volume":"187","author":"M Achom","year":"2024","unstructured":"Achom, M. et al. A genetic basis for sex differences in Xp11 translocation renal cell carcinoma. Cell 187, 5735\u20135752.e25 (2024).","journal-title":"Cell"},{"key":"76858_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25618-z","volume":"12","author":"G Sun","year":"2021","unstructured":"Sun, G. et al. Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma. Nat. Commun. 12, 5262 (2021).","journal-title":"Nat. Commun."},{"key":"76858_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34460-w","volume":"13","author":"Y Qu","year":"2022","unstructured":"Qu, Y. et al. Proteogenomic characterization of MiT family translocation renal cell carcinoma. Nat. Commun. 13, 7494 (2022).","journal-title":"Nat. Commun."},{"key":"76858_CR24","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1158\/1078-0432.CCR-13-3036","volume":"20","author":"GG Malouf","year":"2014","unstructured":"Malouf, G. G. et al. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes. Clin. Cancer Res. 20, 4129\u20134140 (2014).","journal-title":"Clin. Cancer Res."},{"key":"76858_CR25","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1158\/1078-0432.CCR-12-3825","volume":"19","author":"GG Malouf","year":"2013","unstructured":"Malouf, G. G. et al. Genomic heterogeneity of translocation renal cell carcinoma. Clin. Cancer Res. 19, 4673\u20134684 (2013).","journal-title":"Clin. Cancer Res."},{"key":"76858_CR26","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1158\/1078-0432.CCR-19-3283","volume":"26","author":"J Marcon","year":"2020","unstructured":"Marcon, J. et al. Comprehensive genomic analysis of translocation renal cell carcinoma reveals copy-number variations as drivers of disease progression. Clin. Cancer Res. 26, 3629\u20133640 (2020).","journal-title":"Clin. Cancer Res."},{"key":"76858_CR27","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1016\/j.cell.2025.04.002","volume":"188","author":"H Lyons","year":"2025","unstructured":"Lyons, H. et al. RNA polymerase II partitioning is a shared feature of diverse oncofusion condensates. Cell 188, 3843\u20133862.e28 (2025).","journal-title":"Cell"},{"key":"76858_CR28","doi-asserted-by":"publisher","first-page":"115539","DOI":"10.1016\/j.celrep.2025.115539","volume":"44","author":"S Cl","year":"2025","unstructured":"Cl, S. et al. TFE3 fusion oncoprotein condensates drive transcriptional reprogramming and cancer progression in translocation renal cell carcinoma. Cell Rep. 44, 115539 (2025).","journal-title":"Cell Rep."},{"key":"76858_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63761-z","volume":"16","author":"L Guo","year":"2025","unstructured":"Guo, L. et al. RNA-mediated condensation of TFE3 oncofusions facilitates transcriptional hub formation to promote translocation renal cell carcinoma. Nat. Commun. 16, 8712 (2025).","journal-title":"Nat. Commun."},{"key":"76858_CR30","doi-asserted-by":"crossref","unstructured":"Li, J. et al. Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinoma. Nat. Metab. 7, 478\u2013492 (2025).","DOI":"10.1038\/s42255-025-01218-9"},{"key":"76858_CR31","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s44321-025-00221-7","volume":"17","author":"A Helleux","year":"2025","unstructured":"Helleux, A. et al. TFE3 fusions drive oxidative metabolism and ferroptosis resistance in translocation renal cell carcinoma. EMBO Mol. Med. 17, 1041\u20131070 (2025).","journal-title":"EMBO Mol. Med."},{"key":"76858_CR32","doi-asserted-by":"publisher","first-page":"5977","DOI":"10.1158\/1078-0432.CCR-18-0269","volume":"24","author":"NP Damayanti","year":"2018","unstructured":"Damayanti, N. P. et al. Therapeutic targeting of TFE3\/IRS-1\/PI3K\/mTOR axis in translocation renal cell carcinoma. Clin. Cancer Res. 24, 5977\u20135989 (2018).","journal-title":"Clin. Cancer Res."},{"key":"76858_CR33","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1158\/1541-7786.MCR-18-1235","volume":"17","author":"M Baba","year":"2019","unstructured":"Baba, M. et al. TFE3 Xp11.2 translocation renal cell carcinoma mouse model reveals novel therapeutic targets and identifies GPNMB as a diagnostic marker for human disease. Mol. Cancer Res. 17, 1613\u20131626 (2019).","journal-title":"Mol. Cancer Res."},{"key":"76858_CR34","doi-asserted-by":"publisher","first-page":"e17047","DOI":"10.7554\/eLife.17047","volume":"5","author":"A Calcagn\u00ec","year":"2016","unstructured":"Calcagn\u00ec, A. et al. Modelling TFE renal cell carcinoma in mice reveals a critical role of WNT signaling. eLife 5, e17047 (2016).","journal-title":"eLife"},{"key":"76858_CR35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","volume":"23","author":"CJ Ricketts","year":"2018","unstructured":"Ricketts, C. J. et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 23, 313\u2013326.e5 (2018).","journal-title":"Cell Rep."},{"key":"76858_CR36","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","volume":"38","author":"RJ Motzer","year":"2020","unstructured":"Motzer, R. J. et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell 38, 803\u2013817.e4 (2020).","journal-title":"Cancer Cell"},{"key":"76858_CR37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/path.5470","volume":"251","author":"X-T Wang","year":"2020","unstructured":"Wang, X.-T. et al. Malignant melanotic Xp11 neoplasms exhibit a clinicopathologic spectrum and gene expression profiling akin to alveolar soft part sarcoma: a proposal for reclassification. J. Pathol. 251, 365\u2013377 (2020).","journal-title":"J. Pathol."},{"key":"76858_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37211-7","volume":"14","author":"Y Wu","year":"2023","unstructured":"Wu, Y. et al. Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma. Nat. Commun. 14, 1681 (2023).","journal-title":"Nat. Commun."},{"key":"76858_CR39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa1505917","volume":"374","author":"Cancer Genome Atlas Research Networ","year":"2016","unstructured":"Cancer Genome Atlas Research Network et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N. Engl. J. Med. 374, 135\u2013145 (2016).","journal-title":"N. Engl. J. Med."},{"key":"76858_CR40","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.celrep.2016.02.024","volume":"14","author":"F Chen","year":"2016","unstructured":"Chen, F. et al. Multilevel genomics-based taxonomy of renal cell carcinoma. Cell Rep. 14, 2476\u20132489 (2016).","journal-title":"Cell Rep."},{"key":"76858_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1028-7","volume":"17","author":"B Li","year":"2016","unstructured":"Li, B. et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 17, 174 (2016).","journal-title":"Genome Biol."},{"key":"76858_CR42","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"76858_CR43","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1146\/annurev-cancerbio-030518-055835","volume":"3","author":"RM Perera","year":"2019","unstructured":"Perera, R. M., Di Malta, C. & Ballabio, A. MiT\/TFE family of transcription factors, lysosomes, and cancer. Annu. Rev. Cancer Biol. 3, 203\u2013222 (2019).","journal-title":"Annu. Rev. Cancer Biol."},{"key":"76858_CR44","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrurol.2010.47","volume":"7","author":"WM Linehan","year":"2010","unstructured":"Linehan, W. M., Srinivasan, R. & Schmidt, L. S. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol. 7, 277\u2013285 (2010).","journal-title":"Nat. Rev. Urol."},{"key":"76858_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06130-4","author":"A Gavish","year":"2023","unstructured":"Gavish, A. et al. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature https:\/\/doi.org\/10.1038\/s41586-023-06130-4 (2023).","journal-title":"Nature"},{"key":"76858_CR46","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s41588-022-01141-9","volume":"54","author":"D Barkley","year":"2022","unstructured":"Barkley, D. et al. Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment. Nat. Genet. 54, 1192\u20131201 (2022).","journal-title":"Nat. Genet."},{"key":"76858_CR47","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.bone.2003.08.014","volume":"34","author":"CL Hershey","year":"2004","unstructured":"Hershey, C. L. & Fisher, D. E. Mitf and Tfe3: members of a b-HLH-ZIP transcription factor family essential for osteoclast development and function. Bone 34, 689\u2013696 (2004).","journal-title":"Bone"},{"key":"76858_CR48","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1073\/pnas.072071099","volume":"99","author":"E Steingr\u00edmsson","year":"2002","unstructured":"Steingr\u00edmsson, E. et al. Mitf and Tfe3, two members of the Mitf-Tfe family of bHLH-Zip transcription factors, have important but functionally redundant roles in osteoclast development. Proc. Natl. Acad. Sci. USA 99, 4477\u20134482 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76858_CR49","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1080\/15548627.2016.1179405","volume":"12","author":"N Pastore","year":"2016","unstructured":"Pastore, N. et al. TFEB and TFE3 cooperate in the regulation of the innate immune response in activated macrophages. Autophagy 12, 1240\u20131258 (2016).","journal-title":"Autophagy"},{"key":"76858_CR50","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/25785826.2020.1756609","volume":"43","author":"Y Iwasaki","year":"2020","unstructured":"Iwasaki, Y., Takeshima, Y. & Fujio, K. Basic mechanism of immune system activation by mitochondria. Immunol. Med. 43, 142\u2013147 (2020).","journal-title":"Immunol. Med."},{"key":"76858_CR51","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/cr.2011.144","volume":"22","author":"Q Qin","year":"2012","unstructured":"Qin, Q., Xu, Y., He, T., Qin, C. & Xu, J. Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res. 22, 90\u2013106 (2012).","journal-title":"Cell Res."},{"key":"76858_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215689","volume":"538","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Up-regulation of NMRK2 mediated by TFE3 fusions is the key for energy metabolism adaption of Xp11.2 translocation renal cell carcinoma. Cancer Lett. 538, 215689 (2022).","journal-title":"Cancer Lett."},{"key":"76858_CR53","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/path.6340","volume":"264","author":"H Feng","year":"2024","unstructured":"Feng, H. et al. NMRK2 is an efficient diagnostic indicator for Xp11.2 translocation renal cell carcinoma. J. Pathol. 264, 228\u2013240 (2024).","journal-title":"J. Pathol."},{"key":"76858_CR54","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.celrep.2017.07.043","volume":"20","author":"D Lindgren","year":"2017","unstructured":"Lindgren, D. et al. Cell-type-specific gene programs of the normal human nephron define kidney cancer subtypes. Cell Rep. 20, 1476\u20131489 (2017).","journal-title":"Cell Rep."},{"key":"76858_CR55","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1126\/science.aat1699","volume":"361","author":"MD Young","year":"2018","unstructured":"Young, M. D. et al. Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science 361, 594\u2013599 (2018).","journal-title":"Science"},{"key":"76858_CR56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2103240118","volume":"118","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response. Proc. Natl. Acad. Sci. USA 118, e2103240118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76858_CR57","doi-asserted-by":"publisher","unstructured":"Li, G. X. et al. Comprehensive proteogenomic characterization of rare kidney tumors. Cell Rep. Med. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101547 (2024).","DOI":"10.1016\/j.xcrm.2024.101547"},{"key":"76858_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22368-w","volume":"12","author":"Y Muto","year":"2021","unstructured":"Muto, Y. et al. Single cell transcriptional and chromatin accessibility profiling redefine cellular heterogeneity in the adult human kidney. Nat. Commun. 12, 2190 (2021).","journal-title":"Nat. Commun."},{"key":"76858_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10861-2","volume":"10","author":"BB Lake","year":"2019","unstructured":"Lake, B. B. et al. A single-nucleus RNA-sequencing pipeline to decipher the molecular anatomy and pathophysiology of human kidneys. Nat. Commun. 10, 2832 (2019).","journal-title":"Nat. Commun."},{"key":"76858_CR60","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41536-021-00156-w","volume":"6","author":"A Schumacher","year":"2021","unstructured":"Schumacher, A. et al. Defining the variety of cell types in developing and adult human kidneys by single-cell RNA sequencing. npj Regen. Med. 6, 45 (2021).","journal-title":"npj Regen. Med."},{"key":"76858_CR61","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.kint.2019.02.036","volume":"96","author":"VD D\u2019Agati","year":"2019","unstructured":"D\u2019Agati, V. D. & Shankland, S. J. Recognizing diversity in parietal epithelial cells. Kidney Int. 96, 16\u201319 (2019).","journal-title":"Kidney Int."},{"key":"76858_CR62","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.kint.2019.01.037","volume":"96","author":"C Kuppe","year":"2019","unstructured":"Kuppe, C. et al. Novel parietal epithelial cell subpopulations contribute to focal segmental glomerulosclerosis and glomerular tip lesions. Kidney Int. 96, 80\u201393 (2019).","journal-title":"Kidney Int."},{"key":"76858_CR63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026684118","volume":"118","author":"LMS Gerhardt","year":"2021","unstructured":"Gerhardt, L. M. S., Liu, J., Koppitch, K., Cipp\u00e0, P. E. & McMahon, A. P. Single-nuclear transcriptomics reveals diversity of proximal tubule cell states in a dynamic response to acute kidney injury. Proc. Natl. Acad. Sci. USA 118, e2026684118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76858_CR64","doi-asserted-by":"publisher","first-page":"15874","DOI":"10.1073\/pnas.2005477117","volume":"117","author":"Y Kirita","year":"2020","unstructured":"Kirita, Y., Wu, H., Uchimura, K., Wilson, P. C. & Humphreys, B. D. Cell profiling of mouse acute kidney injury reveals conserved cellular responses to injury. Proc. Natl. Acad. Sci. USA 117, 15874\u201315883 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76858_CR65","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1158\/1078-0432.CCR-21-0025","volume":"27","author":"W Xu","year":"2021","unstructured":"Xu, W. et al. Plasma KIM-1 is associated with recurrence risk after nephrectomy for localized renal cell carcinoma: a trial of the ECOG-ACRIN research group (E2805). Clin. Cancer Res. 27, 3397\u20133403 (2021).","journal-title":"Clin. Cancer Res."},{"key":"76858_CR66","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.23.00699","volume":"42","author":"W Xu","year":"2024","unstructured":"Xu, W. et al. Plasma kidney injury molecule-1 for preoperative prediction of renal cell carcinoma versus benign renal masses, and association with clinical outcomes. J. Clin. Oncol. 42, 2691\u20132701 (2024).","journal-title":"J. Clin. Oncol."},{"key":"76858_CR67","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/ndt\/6.12.917","volume":"6","author":"D Seron","year":"1991","unstructured":"Seron, D., Cameron, J. S. & Haskard, D. O. Expression of VCAM-1 in the normal and diseased kidney. Nephrol. Dial. Transplant. 6, 917\u2013922 (1991).","journal-title":"Nephrol. Dial. Transplant."},{"key":"76858_CR68","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41591-020-01212-6","volume":"27","author":"L Jerby-Arnon","year":"2021","unstructured":"Jerby-Arnon, L. et al. Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma. Nat. Med 27, 289\u2013300 (2021).","journal-title":"Nat. Med"},{"key":"76858_CR69","unstructured":"AREN1721, a randomized phase 2 trial of axitinib+nivolumab combination therapy vs. single agent nivolumab for the treatment of TFE\/translocation renal cell carcinoma (tRCC) across all age groups, an NCI National Clinical Trials Network (NCTN) phase 2 study. - ASCO https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT487496."},{"key":"76858_CR70","doi-asserted-by":"publisher","unstructured":"Ribatti, D. Inflammation and angiogenesis. In Inflammation and Angiogenesis 25\u201326 https:\/\/doi.org\/10.1007\/978-3-319-68448-2_6 (Springer, Cham, 2017).","DOI":"10.1007\/978-3-319-68448-2_6"},{"key":"76858_CR71","doi-asserted-by":"crossref","unstructured":"Whiteford, J. R., De Rossi, G. & Woodfin, A. Chapter Six - Mutually supportive mechanisms of inflammation and vascular remodeling. In International Review of Cell and Molecular Biology (eds Jeon, K. W. & Galluzzi, L.) Vol. 326 201\u2013278 (Academic Press, 2016).","DOI":"10.1016\/bs.ircmb.2016.05.001"},{"key":"76858_CR72","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.ccell.2022.11.001","volume":"40","author":"R Li","year":"2022","unstructured":"Li, R. et al. Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer. Cancer Cell 40, 1583\u20131599.e10 (2022).","journal-title":"Cancer Cell"},{"key":"76858_CR73","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-pathol-020117-043854","volume":"13","author":"V Mittal","year":"2018","unstructured":"Mittal, V. Epithelial mesenchymal transition in tumor metastasis. Annu. Rev. Pathol. 13, 395\u2013412 (2018).","journal-title":"Annu. Rev. Pathol."},{"key":"76858_CR74","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41571-025-01058-2","volume":"22","author":"EW Thompson","year":"2025","unstructured":"Thompson, E. W. et al. EMT and cancer: what clinicians should know. Nat. Rev. Clin. Oncol. 22, 711\u2013733 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"76858_CR75","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre, A. & Weinberg, R. A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 20, 69\u201384 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"76858_CR76","doi-asserted-by":"publisher","first-page":"e170559","DOI":"10.1172\/JCI170559","volume":"134","author":"G Prakasam","year":"2024","unstructured":"Prakasam, G. et al. Comparative genomics incorporating translocation renal cell carcinoma mouse model reveals molecular mechanisms of tumorigenesis. J. Clin. Invest. 134, e170559 (2024).","journal-title":"J. Clin. Invest."},{"key":"76858_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63885-2","volume":"16","author":"K Asrani","year":"2025","unstructured":"Asrani, K. et al. SFPQ-TFE3 reciprocally regulates mTORC1 and induces lineage plasticity in a mouse model of renal tumorigenesis. Nat. Commun. 16, 8822 (2025).","journal-title":"Nat. Commun."},{"key":"76858_CR78","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ccr.2013.04.020","volume":"23","author":"N Tiwari","year":"2013","unstructured":"Tiwari, N. et al. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell 23, 768\u2013783 (2013).","journal-title":"Cancer Cell"},{"key":"76858_CR79","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ebiom.2018.04.023","volume":"31","author":"T Zhou","year":"2018","unstructured":"Zhou, T. et al. Runt-related transcription factor 1 (RUNX1) promotes TGF-\u03b2-induced renal tubular epithelial-to-mesenchymal transition (EMT) and renal fibrosis through the PI3K subunit p110\u03b4. eBioMedicine 31, 217\u2013225 (2018).","journal-title":"eBioMedicine"},{"key":"76858_CR80","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2131","volume":"7","author":"H Peinado","year":"2007","unstructured":"Peinado, H., Olmeda, D. & Cano, A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 7, 415\u2013428 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"76858_CR81","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.semcancer.2015.09.010","volume":"35","author":"J Dittmer","year":"2015","unstructured":"Dittmer, J. The role of the transcription factor Ets1 in carcinoma. Semin. Cancer Biol. 35, 20\u201338 (2015).","journal-title":"Semin. Cancer Biol."},{"key":"76858_CR82","doi-asserted-by":"publisher","first-page":"13355","DOI":"10.1074\/jbc.M900843200","volume":"284","author":"H Zhang","year":"2009","unstructured":"Zhang, H. et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition*. J. Biol. Chem. 284, 13355\u201313362 (2009).","journal-title":"J. Biol. Chem."},{"key":"76858_CR83","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1681\/ASN.2020020184","volume":"31","author":"SS Marable","year":"2020","unstructured":"Marable, S. S., Chung, E. & Park, J.-S. Hnf4a is required for the development of Cdh6-expressing progenitors into proximal tubules in the mouse kidney. J. Am. Soc. Nephrol. 31, 2543\u20132558 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"76858_CR84","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1387\/ijdb.10535325","volume":"43","author":"GR Dressler","year":"1999","unstructured":"Dressler, G. R. & Woolf, A. S. Pax2 in development and renal disease. Int. J. Dev. Biol. 43, 463\u2013468 (1999).","journal-title":"Int. J. Dev. Biol."},{"key":"76858_CR85","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s00467-018-3990-7","volume":"34","author":"S Ferr\u00e8","year":"2019","unstructured":"Ferr\u00e8, S. & Igarashi, P. New insights into the role of HNF-1\u03b2 in kidney (patho)physiology. Pediatr. Nephrol. 34, 1325\u20131335 (2019).","journal-title":"Pediatr. Nephrol."},{"key":"76858_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116181","volume":"228","author":"LH Lash","year":"2024","unstructured":"Lash, L. H. Renal glutathione: dual roles as antioxidant protector and bioactivation promoter. Biochem. Pharm. 228, 116181 (2024).","journal-title":"Biochem. Pharm."},{"key":"76858_CR87","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.3390\/cancers15153806","volume":"15","author":"C Nze","year":"2023","unstructured":"Nze, C. et al. A phase II clinical trial of pembrolizumab efficacy and safety in advanced renal medullary carcinoma. Cancers 15, 3806 (2023).","journal-title":"Cancers"},{"key":"76858_CR88","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.ccell.2023.07.006","volume":"41","author":"EP Henske","year":"2023","unstructured":"Henske, E. P., Cheng, L., Hakimi, A. A., Choueiri, T. K. & Braun, D. A. Chromophobe renal cell carcinoma. Cancer Cell 41, 1383\u20131388 (2023).","journal-title":"Cancer Cell"},{"key":"76858_CR89","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","volume":"24","author":"L Albiges","year":"2023","unstructured":"Albiges, L. et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 24, 881\u2013891 (2023).","journal-title":"Lancet Oncol."},{"key":"76858_CR90","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1200\/JCO.2024.42.4_suppl.476","volume":"42","author":"C Labaki","year":"2024","unstructured":"Labaki, C. et al. Cellular and molecular determinants of limited anti-tumor immunity in chromophobe renal carcinoma (ChRCC). JCO 42, 476\u2013476 (2024).","journal-title":"JCO"},{"key":"76858_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23324-4","volume":"12","author":"M Andreatta","year":"2021","unstructured":"Andreatta, M. et al. Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nat. Commun. 12, 2965 (2021).","journal-title":"Nat. Commun."},{"key":"76858_CR92","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s41590-023-01510-4","volume":"24","author":"M K\u00fcnzli","year":"2023","unstructured":"K\u00fcnzli, M. & Masopust, D. CD4+ T cell memory. Nat. Immunol. 24, 903\u2013914 (2023).","journal-title":"Nat. Immunol."},{"key":"76858_CR93","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","volume":"55","author":"M Meylan","year":"2022","unstructured":"Meylan, M. et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55, 527\u2013541.e5 (2022).","journal-title":"Immunity"},{"key":"76858_CR94","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1158\/2159-8290.CD-24-0991","volume":"15","author":"MB Hugaboom","year":"2025","unstructured":"Hugaboom, M. B. et al. Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma. Cancer Discov. 15, 948\u2013968 (2025).","journal-title":"Cancer Discov."},{"key":"76858_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104105","volume":"10","author":"W Xu","year":"2025","unstructured":"Xu, W. et al. Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes. ESMO Open 10, 104105 (2025).","journal-title":"ESMO Open"},{"key":"76858_CR96","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019).","journal-title":"Nat. Immunol."},{"key":"76858_CR97","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998\u20131013.e20 (2018).","journal-title":"Cell"},{"key":"76858_CR98","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/icb.2015.9","volume":"93","author":"P-H Lee","year":"2015","unstructured":"Lee, P.-H. et al. G0S2 modulates homeostatic proliferation of na\u00efve CD8+ T cells and inhibits oxidative phosphorylation in mitochondria. Immunol. Cell Biol. 93, 605\u2013615 (2015).","journal-title":"Immunol. Cell Biol."},{"key":"76858_CR99","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s00018-024-05338-5","volume":"81","author":"L Zhang","year":"2024","unstructured":"Zhang, L. et al. CD74 is a functional MIF receptor on activated CD4+ T cells. Cell Mol. Life Sci. 81, 296 (2024).","journal-title":"Cell Mol. Life Sci."},{"key":"76858_CR100","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2304319120","volume":"120","author":"G Micevic","year":"2023","unstructured":"Micevic, G. et al. IL-7R licenses a population of epigenetically poised memory CD8+ T cells with superior antitumor efficacy that are critical for melanoma memory. Proc. Natl. Acad. Sci. USA 120, e2304319120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76858_CR101","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1038\/s41590-020-0791-5","volume":"21","author":"G Galletti","year":"2020","unstructured":"Galletti, G. et al. Two subsets of stem-like CD8+ memory T cell progenitors with distinct fate commitments in humans. Nat. Immunol. 21, 1552\u20131562 (2020).","journal-title":"Nat. Immunol."},{"key":"76858_CR102","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/eji.201948405","volume":"50","author":"EY Chiang","year":"2020","unstructured":"Chiang, E. Y. et al. CD96 functions as a co-stimulatory receptor to enhance CD8+ T cell activation and effector responses. Eur. J. Immunol. 50, 891\u2013902 (2020).","journal-title":"Eur. J. Immunol."},{"key":"76858_CR103","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1111\/ajt.16684","volume":"22","author":"A Connor","year":"2022","unstructured":"Connor, A. & Li, X. C. RASA2 a new gatekeeper for TCR signaling. Am. J. Transplant. 22, 2715 (2022).","journal-title":"Am. J. Transplant."},{"key":"76858_CR104","doi-asserted-by":"publisher","first-page":"216.8","DOI":"10.4049\/jimmunol.194.Supp.216.8","volume":"194","author":"F Carrette","year":"2015","unstructured":"Carrette, F., Tinoco, R., Barraza, M. & Bradley, L. CD44 controls T cell exhaustion and viral persistence during chronic viral infection (VIR10P.1170). J. Immunol. 194, 216.8 (2015).","journal-title":"J. Immunol."},{"key":"76858_CR105","doi-asserted-by":"publisher","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","volume":"6","author":"Y Jiang","year":"2015","unstructured":"Jiang, Y., Li, Y. & Zhu, B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 6, e1792\u2013e1792 (2015).","journal-title":"Cell Death Dis."},{"key":"76858_CR106","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41577-019-0203-y","volume":"20","author":"NM Chapman","year":"2020","unstructured":"Chapman, N. M., Boothby, M. R. & Chi, H. Metabolic coordination of T cell quiescence and activation. Nat. Rev. Immunol. 20, 55\u201370 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"76858_CR107","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.coi.2014.01.006","volume":"27","author":"JA Maciolek","year":"2014","unstructured":"Maciolek, J. A., Alex Pasternak, J. & Wilson, H. L. Metabolism of activated T lymphocytes. Curr. Opin. Immunol. 27, 60\u201374 (2014).","journal-title":"Curr. Opin. Immunol."},{"key":"76858_CR108","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","volume":"21","author":"SA Lasser","year":"2024","unstructured":"Lasser, S. A., Ozbay Kurt, F. G., Arkhypov, I., Utikal, J. & Umansky, V. Myeloid-derived suppressor cells in cancer and cancer therapy. Nat. Rev. Clin. Oncol. 21, 147\u2013164 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"76858_CR109","doi-asserted-by":"crossref","unstructured":"Lyu, A. et al. Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature 637, 1207\u20131217 (2025).","DOI":"10.1038\/s41586-024-08290-3"},{"key":"76858_CR110","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1126\/science.ade2292","volume":"381","author":"R Bill","year":"2023","unstructured":"Bill, R. et al. CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers. Science 381, 515\u2013524 (2023).","journal-title":"Science"},{"key":"76858_CR111","doi-asserted-by":"publisher","first-page":"111929","DOI":"10.1016\/j.celrep.2022.111929","volume":"42","author":"Y Ozato","year":"2023","unstructured":"Ozato, Y. et al. Spatial and single-cell transcriptomics decipher the cellular environment containing HLA-G+ cancer cells and SPP1+ macrophages in colorectal cancer. Cell Rep. 42, 111929 (2023).","journal-title":"Cell Rep."},{"key":"76858_CR112","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.cell.2018.09.030","volume":"175","author":"MM Gubin","year":"2018","unstructured":"Gubin, M. M. et al. High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell 175, 1014\u20131030.e19 (2018).","journal-title":"Cell"},{"key":"76858_CR113","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng, S. et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 184, 792\u2013809.e23 (2021).","journal-title":"Cell"},{"key":"76858_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39762-1","volume":"14","author":"L Cords","year":"2023","unstructured":"Cords, L. et al. Cancer-associated fibroblast classification in single-cell and spatial proteomics data. Nat. Commun. 14, 4294 (2023).","journal-title":"Nat. Commun."},{"key":"76858_CR115","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai, E. et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer 20, 174\u2013186 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"76858_CR116","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/gutjnl-2024-333617","volume":"74","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases. Gut 74, 350\u2013363 (2025).","journal-title":"Gut"},{"key":"76858_CR117","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-022-05272-1","volume":"611","author":"AT Krishnamurty","year":"2022","unstructured":"Krishnamurty, A. T. et al. LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature 611, 148\u2013154 (2022).","journal-title":"Nature"},{"key":"76858_CR118","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ccell.2021.03.012","volume":"39","author":"S Affo","year":"2021","unstructured":"Affo, S. et al. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell 39, 866\u2013882.e11 (2021).","journal-title":"Cancer Cell"},{"key":"76858_CR119","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","volume":"33","author":"A Costa","year":"2018","unstructured":"Costa, A. et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 33, 463\u2013479.e10 (2018).","journal-title":"Cancer Cell"},{"key":"76858_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21055","volume":"9","author":"Z Yan","year":"2023","unstructured":"Yan, Z., Hu, X., Tang, B. & Deng, F. Role of osteopontin in cancer development and treatment. Heliyon 9, e21055 (2023).","journal-title":"Heliyon"},{"key":"76858_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J. & Werb, Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat. Commun. 11, 5120 (2020).","journal-title":"Nat. Commun."},{"key":"76858_CR122","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1126\/science.1176009","volume":"326","author":"RO Hynes","year":"2009","unstructured":"Hynes, R. O. The extracellular matrix: not just pretty fibrils. Science 326, 1216\u20131219 (2009).","journal-title":"Science"},{"key":"76858_CR123","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.15252\/embr.201439246","volume":"15","author":"MW Pickup","year":"2014","unstructured":"Pickup, M. W., Mouw, J. K. & Weaver, V. M. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 15, 1243\u20131253 (2014).","journal-title":"EMBO Rep."},{"key":"76858_CR124","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ncb3090","volume":"17","author":"W Zhou","year":"2015","unstructured":"Zhou, W. et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat. Cell Biol. 17, 170\u2013182 (2015).","journal-title":"Nat. Cell Biol."},{"key":"76858_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13500","volume":"7","author":"S Khurana","year":"2016","unstructured":"Khurana, S. et al. Outside-in integrin signalling regulates haematopoietic stem cell function via Periostin-Itgav axis. Nat. Commun. 7, 13500 (2016).","journal-title":"Nat. Commun."},{"key":"76858_CR126","doi-asserted-by":"publisher","unstructured":"Limbu, S. & Kumar, A. Antibody-based targeting of the SPP1-CD44 axis in pediatric high-grade glioma through single-cell and structural bioinformatics. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.05.01.651763 (2025).","DOI":"10.1101\/2025.05.01.651763"},{"key":"76858_CR127","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.18525","volume":"28","author":"F Liu","year":"2024","unstructured":"Liu, F., Zhang, J., Gu, X., Guo, Q. & Guo, W. Single-cell transcriptome sequencing reveals SPP1-CD44-mediated macrophage\u2013tumor cell interactions drive chemoresistance in TNBC. J. Cell. Mol. Med. 28, e18525 (2024).","journal-title":"J. Cell. Mol. Med."},{"key":"76858_CR128","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-06018-5","volume":"22","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. Single-cell and spatial transcriptomics reveal SPP1-CD44 signaling drives primary resistance to immune checkpoint inhibitors in RCC. J. Transl. Med. 22, 1157 (2024).","journal-title":"J. Transl. Med."},{"key":"76858_CR129","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05613-w","volume":"22","author":"W Tong","year":"2024","unstructured":"Tong, W. et al. Spatial transcriptomics reveals tumor-derived SPP1 induces fibroblast chemotaxis and activation in the hepatocellular carcinoma microenvironment. J. Transl. Med. 22, 840 (2024).","journal-title":"J. Transl. Med."},{"key":"76858_CR130","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.ajpath.2013.11.020","volume":"184","author":"M Yin","year":"2014","unstructured":"Yin, M. et al. Osteopontin promotes the invasive growth of melanoma cells by activating integrin \u03b1v\u03b23 and down-regulating tetraspanin CD9. Am. J. Pathol. 184, 842\u2013858 (2014).","journal-title":"Am. J. Pathol."},{"key":"76858_CR131","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/s12276-024-01291-2","volume":"56","author":"C-R Lee","year":"2024","unstructured":"Lee, C.-R. et al. Comprehensive molecular characterization of TFE3-rearranged renal cell carcinoma. Exp. Mol. Med. 56, 1807\u20131815 (2024).","journal-title":"Exp. Mol. Med."},{"key":"76858_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16066-2","volume":"11","author":"DP Cook","year":"2020","unstructured":"Cook, D. P. & Vanderhyden, B. C. Context specificity of the EMT transcriptional response. Nat. Commun. 11, 2142 (2020).","journal-title":"Nat. Commun."},{"key":"76858_CR133","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/j.celrep.2020.01.049","volume":"30","author":"M-M Aynaud","year":"2020","unstructured":"Aynaud, M.-M. et al. Transcriptional programs define intratumoral heterogeneity of Ewing sarcoma at single-cell resolution. Cell Rep. 30, 1767\u20131779.e6 (2020).","journal-title":"Cell Rep."},{"key":"76858_CR134","doi-asserted-by":"publisher","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-23-1111","volume":"29","author":"ED Wrenn","year":"2023","unstructured":"Wrenn, E. D. et al. Cancer-associated fibroblast-like tumor cells remodel the Ewing sarcoma tumor microenvironment. Clin. Cancer Res. 29, 5140\u20135154 (2023).","journal-title":"Clin. Cancer Res."},{"key":"76858_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50527-2","volume":"15","author":"SG Danielli","year":"2024","unstructured":"Danielli, S. G. et al. Single cell transcriptomic profiling identifies tumor-acquired and therapy-resistant cell states in pediatric rhabdomyosarcoma. Nat. Commun. 15, 6307 (2024).","journal-title":"Nat. Commun."},{"key":"76858_CR136","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/s43018-022-00414-w","volume":"3","author":"Y Wei","year":"2022","unstructured":"Wei, Y. et al. Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma. Nat. Cancer 3, 961\u2013975 (2022).","journal-title":"Nat. Cancer"},{"key":"76858_CR137","doi-asserted-by":"publisher","first-page":"112401","DOI":"10.1016\/j.celrep.2023.112401","volume":"42","author":"C Liu","year":"2023","unstructured":"Liu, C., Kudo, T., Ye, X. & Gascoigne, K. Cell-to-cell variability in Myc dynamics drives transcriptional heterogeneity in cancer cells. Cell Rep. 42, 112401 (2023).","journal-title":"Cell Rep."},{"key":"76858_CR138","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1097\/PAS.0b013e3181f17ac0","volume":"34","author":"P Argani","year":"2010","unstructured":"Argani, P. et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am. J. Surg. Pathol. 34, 1395\u20131406 (2010).","journal-title":"Am. J. Surg. Pathol."},{"key":"76858_CR139","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/gcc.22755","volume":"58","author":"AJH Suurmeijer","year":"2019","unstructured":"Suurmeijer, A. J. H. et al. Novel recurrent PHF1-TFE3 fusions in ossifying fibromyxoid tumors. Genes, Chromosomes Cancer 58, 643\u2013649 (2019).","journal-title":"Genes, Chromosomes Cancer"},{"key":"76858_CR140","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/gcc.22073","volume":"52","author":"CR Antonescu","year":"2013","unstructured":"Antonescu, C. R. et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer 52, 775\u2013784 (2013).","journal-title":"Genes Chromosomes Cancer"},{"key":"76858_CR141","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/gcc.22803","volume":"59","author":"BC Dickson","year":"2020","unstructured":"Dickson, B. C. et al. Genetic diversity in alveolar soft part sarcoma: a subset contain variant fusion genes, highlighting broader molecular kinship with other MiT family tumors. Genes Chromosomes Cancer 59, 23\u201329 (2020).","journal-title":"Genes Chromosomes Cancer"},{"key":"76858_CR142","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/sj.onc.1204074","volume":"20","author":"M Ladanyi","year":"2001","unstructured":"Ladanyi, M. et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 20, 48\u201357 (2001).","journal-title":"Oncogene"},{"key":"76858_CR143","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0482-z","volume":"6","author":"A Boil\u00e8ve","year":"2018","unstructured":"Boil\u00e8ve, A. et al. Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders. J. Immunother. Cancer 6, 159 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"76858_CR144","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1158\/0008-5472.CAN-14-1990","volume":"75","author":"Y Sharon","year":"2015","unstructured":"Sharon, Y. et al. Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer. Cancer Res. 75, 963\u2013973 (2015).","journal-title":"Cancer Res."},{"key":"76858_CR145","doi-asserted-by":"publisher","first-page":"333","DOI":"10.18632\/oncotarget.27881","volume":"12","author":"K Tokuda","year":"2021","unstructured":"Tokuda, K. et al. The interaction between cancer associated fibroblasts and tumor associated macrophages via the osteopontin pathway in the tumor microenvironment of hepatocellular carcinoma. Oncotarget 12, 333\u2013343 (2021).","journal-title":"Oncotarget"},{"key":"76858_CR146","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0674-8","volume":"18","author":"K Xu","year":"2016","unstructured":"Xu, K. et al. The fibroblast Tiam1-osteopontin pathway modulates breast cancer invasion and metastasis. Breast Cancer Res. 18, 14 (2016).","journal-title":"Breast Cancer Res."},{"key":"76858_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29366-6","volume":"13","author":"J Qi","year":"2022","unstructured":"Qi, J. et al. Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1+ macrophages in colorectal cancer. Nat. Commun. 13, 1742 (2022).","journal-title":"Nat. Commun."},{"key":"76858_CR148","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.yexcr.2017.08.028","volume":"359","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y., Du, W., Chen, Z. & Xiang, C. Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma. Exp. Cell Res. 359, 449\u2013457 (2017).","journal-title":"Exp. Cell Res."},{"key":"76858_CR149","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1158\/2326-6066.CIR-24-1146","volume":"13","author":"W Jiang","year":"2025","unstructured":"Jiang, W. et al. SPP1+ tumor-associated macrophages drive immunotherapy resistance via CD8+ T-cell dysfunction in clear-cell renal cell carcinoma. Cancer Immunol. Res. 13, 1533\u20131546 (2025).","journal-title":"Cancer Immunol. Res."},{"key":"76858_CR150","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1158\/2159-8290.CD-20-0603","volume":"11","author":"A Dongre","year":"2021","unstructured":"Dongre, A. et al. Direct and indirect regulators of epithelial\u2013mesenchymal transition\u2013mediated immunosuppression in breast carcinomas. Cancer Discov. 11, 1286\u20131305 (2021).","journal-title":"Cancer Discov."},{"key":"76858_CR151","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-015-0281-z","volume":"35","author":"Y Hu","year":"2016","unstructured":"Hu, Y. et al. Tumor-associated macrophages correlate with the clinicopathological features and poor outcomes via inducing epithelial to mesenchymal transition in oral squamous cell carcinoma. J. Exp. Clin. Cancer Res. 35, 12 (2016).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"76858_CR152","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ccr.2013.08.001","volume":"24","author":"KPL Bhat","year":"2013","unstructured":"Bhat, K. P. L. et al. Mesenchymal differentiation mediated by NF-\u03baB promotes radiation resistance in glioblastoma. Cancer Cell 24, 331\u2013346 (2013).","journal-title":"Cancer Cell"},{"key":"76858_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-019-2131-y","volume":"10","author":"W Li","year":"2019","unstructured":"Li, W. et al. Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer. Cell Death Dis. 10, 1\u201316 (2019).","journal-title":"Cell Death Dis."},{"key":"76858_CR154","doi-asserted-by":"publisher","first-page":"e34119","DOI":"10.1016\/j.heliyon.2024.e34119","volume":"10","author":"P Feng","year":"2024","unstructured":"Feng, P., Liu, S., Yuan, G. & Pan, Y. Association of M2 macrophages with EMT in glioma identified through combination of multi-omics and machine learning. Heliyon 10, e34119 (2024).","journal-title":"Heliyon"},{"key":"76858_CR155","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1158\/0008-5472.CAN-17-2158","volume":"79","author":"A Valeta-Magara","year":"2019","unstructured":"Valeta-Magara, A. et al. Inflammatory breast cancer promotes development of M2 tumor-associated macrophages and cancer mesenchymal cells through a complex chemokine network. Cancer Res. 79, 3360\u20133371 (2019).","journal-title":"Cancer Res."},{"key":"76858_CR156","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2303383","volume":"389","author":"AP Chen","year":"2023","unstructured":"Chen, A. P. et al. Atezolizumab for advanced alveolar soft part sarcoma. N. Engl. J. Med. 389, 911\u2013921 (2023).","journal-title":"N. Engl. J. Med."},{"key":"76858_CR157","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41591-020-0844-1","volume":"26","author":"M Slyper","year":"2020","unstructured":"Slyper, M. et al. A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat. Med. 26, 792\u2013802 (2020).","journal-title":"Nat. Med."},{"key":"76858_CR158","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e29 (2021).","journal-title":"Cell"},{"key":"76858_CR159","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","volume":"8","author":"SL Wolock","year":"2019","unstructured":"Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 8, 281\u2013291.e9 (2019).","journal-title":"Cell Syst."},{"key":"76858_CR160","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"76858_CR161","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"76858_CR162","unstructured":"broadinstitute. InferCNV. GitHub https:\/\/github.com\/broadinstitute\/infercnv\/wiki\/Home."},{"key":"76858_CR163","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30755-0","volume":"13","author":"D Dimitrov","year":"2022","unstructured":"Dimitrov, D. et al. Comparison of methods and resources for cell-cell communication inference from single-cell RNA-Seq data. Nat. Commun. 13, 3224 (2022).","journal-title":"Nat. Commun."},{"key":"76858_CR164","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41596-024-01020-z","volume":"19","author":"S Xu","year":"2024","unstructured":"Xu, S. et al. Using clusterProfiler to characterize multiomics data. Nat. Protoc. 19, 3292\u20133320 (2024).","journal-title":"Nat. Protoc."},{"key":"76858_CR165","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie, Z. et al. Gene set knowledge discovery with enrichr. Curr. Protoc. 1, e90 (2021).","journal-title":"Curr. Protoc."},{"key":"76858_CR166","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1038\/s41596-020-0336-2","volume":"15","author":"B Van de Sande","year":"2020","unstructured":"Van de Sande, B. et al. A scalable SCENIC workflow for single-cell gene regulatory network analysis. Nat. Protoc. 15, 2247\u20132276 (2020).","journal-title":"Nat. Protoc."},{"key":"76858_CR167","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41592-021-01282-5","volume":"18","author":"T Stuart","year":"2021","unstructured":"Stuart, T., Srivastava, A., Madad, S., Lareau, C. A. & Satija, R. Single-cell chromatin state analysis with Signac. Nat. Methods 18, 1333\u20131341 (2021).","journal-title":"Nat. Methods"},{"key":"76858_CR168","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-9-r137","volume":"9","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).","journal-title":"Genome Biol."},{"key":"76858_CR169","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li, T. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48, W509\u2013W514 (2020).","journal-title":"Nucleic Acids Res."},{"key":"76858_CR170","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1038\/s41596-024-01137-1","volume":"20","author":"K Troul\u00e9","year":"2025","unstructured":"Troul\u00e9, K. et al. CellPhoneDB v5: inferring cell-cell communication from single-cell multiomics data. Nat. Protoc. 20, 3412\u20133440 (2025).","journal-title":"Nat. Protoc."},{"key":"76858_CR171","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1038\/s41596-019-0195-x","volume":"14","author":"S Li","year":"2019","unstructured":"Li, S. et al. RNase H-dependent PCR-enabled T-cell receptor sequencing for highly specific and efficient targeted sequencing of T-cell receptor mRNA for single-cell and repertoire analysis. Nat. Protoc. 14, 2571\u20132594 (2019).","journal-title":"Nat. Protoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76858-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76858-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76858-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:03:17Z","timestamp":1790294597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76858-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":171,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76858"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76858-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.R.V.: Involved in institutional patent applications on detection of molecular alterations in ctDNA and therapeutic targeting of cancer vulnerabilities and tRCC, unrelated to the current study; research support from Akebia Therapeutics\u00a0and Kura Oncology. Consulting: Iylon Precision Oncology. Completed within past 3 years: research support from Bayer. T.K.C. reports institutional and\/or personal, paid and\/or unpaid support research, advisory boards, consultancy, and\/or honoraria in the past 5 years, ongoing or not from Alkermes, Arcus Bio, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Bicycle Therapeutics, Calithera, Caris, Circle Pharma, Deciphera Pharmaceuticals, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, HiberCell, IQVA, Infinity, Institut Servier, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Neomorph, Nuscan\/PrecedeBio, Novartis, Oncohost, Pfizer, Roche, Sanofi\/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME and non-CME events (Mashup Media, Elite Elements, Peerview, OncLive, MJH, CCO and others), Xencor, outside the submitted work. T.K.C. is involved in institutional patents filed on molecular alterations and immunotherapy response\/toxicity, rare genitourinary cancers, and ctDNA\/liquid biopsies. T.K.C. reports equity from Tempest, Pionyr, Osel, Precede Bio, CureResponse, InnDura Therapeutics, Primium, Abalytics, Faron Pharma, Open Medicine. T.K.C. is on committees for NCCN, GU Steering Committee, ASCO (BOD 6-2024-), ESMO, ACCRU, KidneyCan. T.K.C. mentored several non-US citizens on research projects with potential funding (in part) from non-US sources\/Foreign Components. S.S. reports receiving commercial research grants from Bristol-Myers Squibb, AstraZeneca, Exelixis, Merck, NiKang Therapeutics, and Arsenal Biosciences; is a consultant\/advisory board member for Merck, AstraZeneca, Bristol Myers Squibb, NextPoint Therapeutics, AACR, and NCI; receives royalties from Biogenex; and mentored several non-US citizens on research projects with potential funding (in part) from non-US sources\/Foreign Components. E.M.V.A. reports advisory\/consulting relationships with Enara Bio, Manifold Bio, Monte Rosa, Novartis Institute for Biomedical Research, Serinus Bio, and TracerBio. E.M.V.A. has received research support from Novartis, BMS, Sanofi, and NextPoint. E.M.V.A. holds equity in Tango Therapeutics, Genome Medical, Genomic Life, Enara Bio, Manifold Bio, Microsoft, Monte Rosa, Riva Therapeutics, Serinus Bio, Syapse, and TracerDx. E.M.V.A. is involved in institutional patents filed on chromatin mutations and immunotherapy response, as well as methods for clinical interpretation, and provides intermittent legal consulting on patents for Foaley & Hoag. E.M.V.A. serves on the editorial board of Science Advances. C.-Z.Z. is a co-founder and equity holder of Pillar Biosciences, a for-profit company specialized in assay development for targeted DNA sequencing. D.J.E. received research funding to institution from Bristol-Myers Squibb, Cardiff Oncology, Iovance, MiNK Therapeutics, Novartis, Sanofi, and Puma Biotech; discounted research sequencing from Foundation Medicine; consulting honorarium from Bayer, Jansen, Nimbus Therapeutics, and Xilio.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10191"}}